- Home
- YHGJ vs JAGX Comparison
YHGJ vs JAGX Comparison
Compare YHGJ & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- JAGX
- Stock Information
- Founded
- YHGJ 1975
- JAGX 2013
- Country
- YHGJ United States
- JAGX United States
- Employees
- YHGJ N/A
- JAGX N/A
- Industry
- YHGJ Specialty Chemicals
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- JAGX Health Care
- Exchange
- YHGJ Nasdaq
- JAGX Nasdaq
- Market Cap
- YHGJ 15.8M
- JAGX 12.9M
- IPO Year
- YHGJ 1997
- JAGX N/A
- Fundamental
- Price
- YHGJ $1.02
- JAGX $0.45
- Analyst Decision
- YHGJ
- JAGX
- Analyst Count
- YHGJ 0
- JAGX 0
- Target Price
- YHGJ N/A
- JAGX N/A
- AVG Volume (30 Days)
- YHGJ 41.7K
- JAGX 405.5K
- Earning Date
- YHGJ 03-21-2025
- JAGX 03-31-2025
- Dividend Yield
- YHGJ N/A
- JAGX N/A
- EPS Growth
- YHGJ N/A
- JAGX N/A
- EPS
- YHGJ N/A
- JAGX N/A
- Revenue
- YHGJ $18,559,000.00
- JAGX $10,480,000.00
- Revenue This Year
- YHGJ N/A
- JAGX $18.18
- Revenue Next Year
- YHGJ N/A
- JAGX $40.06
- P/E Ratio
- YHGJ N/A
- JAGX N/A
- Revenue Growth
- YHGJ 11.78
- JAGX N/A
- 52 Week Low
- YHGJ $0.43
- JAGX $0.44
- 52 Week High
- YHGJ $1.85
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- YHGJ 78.94
- JAGX 26.15
- Support Level
- YHGJ $0.58
- JAGX $0.57
- Resistance Level
- YHGJ $0.69
- JAGX $0.60
- Average True Range (ATR)
- YHGJ 0.08
- JAGX 0.07
- MACD
- YHGJ 0.03
- JAGX -0.02
- Stochastic Oscillator
- YHGJ 93.62
- JAGX 2.14
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.